Uploaded November 2025 | Updated September 2026, 2 weeks ago

---

Hosted by Ian Khan, a globally recognised futurist and technology expert, this Future Investment Initiative (FII 2025) interview explores how AI and biotech are converging to revolutionise healthcare, precision medicine and drug development. Ian engages with Dr. Thomas Clozel to uncover the strategic, technological and human‑impact dimensions of this transformation.

Dr. Thomas Clozel is the Co‑Founder & Chief Executive Officer of Owkin, a French‑American AI‑biotech company that uses federated learning and multimodal patient data to accelerate drug discovery, develop diagnostics, and enhance patient outcomes. A former assistant professor of clinical onco‑hematology in Paris and researcher at Weill Cornell, Dr. Clozel leads the mission to “find the right treatment for every patient” through innovative AI‑driven platforms.

🔗 Stay Connected:

Buy a Copy of My New Book UNDUSRUPTED amzn.to/4g5gjH9

Visit my website: iankhan.com
Follow me on Twitter: twitter.com/IanKhanFuturist
Follow me on LinkedIn: linkedin.com/in/iankhanfuturist
Follow me on Facebook: facebook.com/iankhanfuturist